Lilly (LLY) says solanezumab did not slow the progression of cognitive decline due to Alzheimer's disease in latest study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. MU
6. USO
7. APGE
8. ABBV
9. NAVN
10. DFTX

Go back to Lilly (LLY) says solanezumab did not slow the progression of cognitive decline due to Alzheimer's disease in latest study
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1102.08 --0 (-0%)
Previous Close $1102.08    52 Week High $88.16 
Open $1102.08    52 Week Low $67.88 
Day High $1102.08    P/E 255.11 
Day Low $1102.08    EPS $4.32 
Volume 4,823